IsoPlexis - ISO Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoPlexis in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ISO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISO, but not buy additional shares or sell existing shares.
View ISO analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price targets for IsoPlexis' shares. Their ISO share price forecasts range from $1.50 to $1.70. On average, they expect the company's stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price.
View analysts price targets for ISO or view top-rated stocks among Wall Street analysts.

IsoPlexis' stock was trading at $1.55 at the start of the year. Since then, ISO shares have decreased by 50.9% and is now trading at $0.7616.
View the best growth stocks for 2023 here.

IsoPlexis saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 115,500 shares, a decrease of 42.8% from the February 13th total of 201,800 shares. Based on an average trading volume of 923,200 shares, the short-interest ratio is presently 0.1 days. Approximately 0.7% of the shares of the stock are sold short.
View IsoPlexis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ISO earnings forecast.

IsoPlexis Co. (NASDAQ:ISO) released its quarterly earnings results on Thursday, March, 2nd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.45. The business earned $3.36 million during the quarter, compared to the consensus estimate of $5.92 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.

IsoPlexis updated its FY 2022 earnings guidance on Sunday, January, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16.60 million-$16.80 million, compared to the consensus revenue estimate of $19.51 million.

(ISO) raised $125 million in an initial public offering on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share.

IsoPlexis trades on the NASDAQ under the ticker symbol "ISO."

IsoPlexis' stock is owned by a number of institutional and retail investors. Top institutional investors include Glenview Capital Management LLC (4.98%), Norges Bank (1.59%), Morgan Stanley (1.28%), Crystalline Management Inc. (0.70%), Geode Capital Management LLC (0.39%) and JBF Capital Inc. (0.33%). Insiders that own company stock include John Strahley, Nachum Shamir, Richard W Rew II and Sean Mackay.
View institutional ownership trends.

Shares of ISO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISO stock can currently be purchased for approximately $0.76.

IsoPlexis (NASDAQ:ISO) has a market capitalization of $30.28 million and generates $16.76 million in revenue each year. The company earns $-106,000,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

The company employs 459 workers across the globe.

IsoPlexis' mailing address is 35 NE INDUSTRIAL ROAD, BRANFORD CT, 06405. The official website for the company is isoplexis.com. The company can be reached via phone at 203-208-4111 or via email at investors@isoplexis.com.